The new platform, described in Advanced Science, addresses a long-standing gap in preclinical cancer research. The standard approach of growing tumors under the skin of mice fails to reproduce the brain’s unique extracellular matrix, immune environment, and drug delivery constraints, because the blood–brain barrier simply is not present in a subcutaneous model. Orthotopic models, in which tumor cells are surgically implanted into the brain, offer better predictive value but demand advanced surgical skill, specialized imaging such as MRI or CT to track tumor growth, and raise significant ethical concerns. In vitro models have improved considerably in recent years, particularly as regulatory agencies have begun approving animal-free alternatives for preclinical testing, but most existing blood–brain barrier models either separate their cellular compartments behind scaffolds or lack tumor cells entirely.

The team used an extrusion-based 3D bioprinter to fabricate polylactic acid microwell chambers coated with agarose, into which they printed mixtures of human cerebral microvascular endothelial cells, human brain vascular pericytes, and U-87 MG glioblastoma cells at a one-to-one-to-one ratio. Within twenty-four hours, the cells spontaneously assembled into compact spheroids roughly 300 micrometers in diameter. Confocal microscopy of spheroids labeled with distinct fluorescent cell trackers revealed a striking self-organized architecture: endothelial cells formed the outermost layer, pericytes occupied an intermediate position, and glioblastoma cells comprised the core. Critically, a substantial fraction of pericytes migrated into the tumor core, and follow-up co-culture experiments demonstrated cytoplasmic mixing between pericytes and tumor cells, a phenomenon documented in real glioblastoma tumors in which cancer cells exploit pericyte interactions to drive progression. Because earlier scaffold-based models physically separated their compartments, they could not reproduce this direct cellular intimacy.

Functionally, the spheroids behaved like the barrier they were meant to mimic. Immunofluorescence imaging showed robust expression of the tight junction proteins ZO-1, occludin, and claudin-5, along with the efflux transporter P-glycoprotein, with more than ninety percent of outer-layer endothelial cells expressing all four proteins. When the researchers applied a 40-kilodalton fluorescent dextran tracer, the blood–brain–tumor barrier spheroids proved less permeable than bare tumor spheroids but slightly more permeable than tumor-free blood–brain barrier spheroids assembled with astrocytes in place of tumor cells. That intermediate, leaky phenotype is precisely what clinicians observe in glioblastoma patients, where tumor-induced vascular changes compromise barrier integrity without eliminating it.

With the model validated, the researchers turned to their candidate drug: a ruthenium(II) polypyridyl complex with a molecular weight of 871.9 grams per mole. Unlike most chemotherapy agents, which target DNA directly, ruthenium compounds kill cancer cells by generating reactive oxygen species such as singlet oxygen and hydroxyl radicals. Cancer cells already operate at elevated oxidative stress levels due to their rapid metabolism and survive only by leaning heavily on antioxidant systems like glutathione. An additional burst of ROS tips that balance into catastrophe, damaging DNA, proteins, and lipids until the cell dies. Confocal imaging showed the ruthenium compound accumulating in mitochondria and the endoplasmic reticulum of U-87 MG cells, and dose-dependent ROS generation was confirmed with a fluorescent probe. The compound triggered mitochondrial permeability transition, disrupted calcium homeostasis, and reduced U-87 MG viability by half at a concentration of 22.3 micromolar.

The most intriguing finding concerned how the compound interacts with the barrier itself. Treatment with the ruthenium complex increased expression of alpha-smooth muscle actin and F-actin in pericytes, promoting contractile changes that loosen barrier structure. It also elevated secretion of matrix metalloproteinase-9, an enzyme that degrades extracellular matrix and erodes tight junctions, and endothelin-1, a vasoconstrictor associated with increased barrier permeability. Tight junction protein levels in endothelial cells dropped significantly at 20 micromolar. When cells were pretreated with the antioxidant N-acetylcysteine, these effects were largely abolished, with the scavenger suppressing 69 to 77 percent of the drug-induced increases in MMP-9 and endothelin-1 and restoring tight junction protein expression nearly to baseline. In other words, the compound appears to open its own path through the barrier via the very reactive oxygen species it generates, facilitating paracellular transport in addition to partial passive diffusion across endothelial cells.

Permeability experiments confirmed this dual mechanism. While the dextran tracer showed roughly 3.5-fold higher fluorescence in tumor-only spheroids than in blood–brain barrier spheroids, the ruthenium compound distributed nearly equally across all three spheroid types, with ratios hovering near 1.0. Transwell assays using endothelial monolayers further showed that the compound is only a partial P-glycoprotein substrate, with an efflux ratio of 1.7-fold upon inhibition, far lower than the 4.4-fold ratio observed for osimertinib, an approved cancer drug that proved unsuitable for brain delivery due to both strong efflux and a narrow therapeutic window. Temozolomide, the current standard of care for glioblastoma, showed no P-glycoprotein involvement at all, crossing exclusively by passive diffusion.

The head-to-head comparison inside the bioprinted spheroids delivered the study’s most striking result. Using a fluorescent cell death probe that itself penetrates the barrier, the researchers quantified tumor cell killing at single-cell resolution within intact spheroids. Paclitaxel and cisplatin, both established chemotherapies, produced negligible cell death, consistent with their inability to cross the blood–brain–tumor barrier. Temozolomide and the ruthenium compound both induced significant tumor cell death, but after normalizing for dose and potency, the ruthenium compound achieved a relative permeability of 14.2 compared with 10.6 for temozolomide, despite being administered at a concentration slightly below its own IC50. Flow cytometry cross-validated these imaging results, showing roughly 21.7 percent tumor cell death for the ruthenium compound versus 19.9 percent for temozolomide, while controls and the two non-penetrant drugs remained near baseline.

The platform also proved adaptable beyond a single laboratory cell line. When the researchers rebuilt the spheroids using two patient-derived glioblastoma cell lines, SNU-4210 and SNU-5026, the same layered architecture emerged, and the ruthenium compound again outperformed temozolomide, generating roughly 2.1 to 2.3 times higher cell death signal across the tumor core. This patient-derived validation matters because glioblastoma is notoriously heterogeneous, and models that only work with established cell lines often fail to predict clinical responses.

The authors are careful to note the caveats. The model measures relative rather than absolute permeability, the 48-hour exposure window may not suit every compound, and barrier opening driven by ROS-mediated tight junction damage is mechanistically distinct from favorable intrinsic penetration, raising questions about the balance between drug delivery and neurovascular safety that will require in vivo evaluation. MMP-9 and endothelin-1 are also pleiotropic mediators involved in tumor invasion and treatment resistance, not simple barrier biomarkers. Even so, the study delivers two significant contributions at once: a bioprinted, scaffold-free model that captures the cellular crosstalk of the tumor-barrier interface, and the first ruthenium-based ROS-generating agent evaluated within such a system, one that killed glioblastoma cells more efficiently per dose than the standard-of-care drug while tolerating concentrations that left endothelial cells unharmed. For a disease where nearly every drug candidate dies at the barrier, both advances deserve close attention.

Subject of Research: A 3D bioprinted blood–brain–tumor barrier spheroid model for evaluating ROS-generating ruthenium anticancer compounds against glioblastoma

Article Title: 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate

Article References: Lee, H., Jeon, C. H., Kim, D., Lee, M., Kwon, M., & Song, J. M. (2026). 3D Bioprinted Blood–Brain–Tumor Barrier Spheroid‐Based In Situ Evaluation of Anticancer Compounds Against Glioblastoma: ROS‐Producing Ruthenium as a Potential Therapeutic Candidate. Advanced Science, Article e78150. https://doi.org/10.1002/advs.78150

Image Credits: AI Generated

DOI: 10.1002/advs.78150

Keywords: glioblastoma, blood-brain barrier, 3D bioprinting, spheroid model, ruthenium compound, reactive oxygen species, blood-brain-tumor barrier, temozolomide, P-glycoprotein, tight junctions, pericytes, drug permeability

The central thesis of the review is that the EGFR–STAT3 axis should not be understood as a simple linear pathway in which a signal travels from receptor to nucleus. Instead, the authors propose that it functions as an adaptive resistance hub, a dynamic network node that integrates inputs from growth factor signaling, inflammatory cytokines, hypoxic stress, tumor-associated macrophages, and the pharmacological pressure exerted by therapy itself. When EGFR is pharmacologically inhibited, the signal transducer and activator of transcription 3, or STAT3, can remain persistently active through alternative routes, sustaining the oncogenic transcriptional programs that EGFR blockade was supposed to shut down. This compensatory activation, the review argues, is the mechanistic heart of adaptive resistance in glioblastoma, and it explains why single-agent EGFR therapies have repeatedly come up short.

To appreciate the significance of this argument, it helps to understand the molecular mechanics involved. Under normal conditions, EGFR activation at the cell membrane triggers a cascade that includes the JAK kinases, which phosphorylate STAT3, allowing it to dimerize, translocate to the nucleus, and switch on genes that promote proliferation, survival, and invasion. In many cancers, this canonical route is the dominant driver of STAT3 activity. But glioblastoma is not an ordinary cancer. The tumor microenvironment of the brain is saturated with alternative activators of STAT3 that operate entirely independently of EGFR. Interleukin-6 and other inflammatory cytokines released by tumor-associated macrophages and microglia can activate the JAK/STAT3 pathway directly. Hypoxia, a hallmark of the glioblastoma microenvironment, has been shown to drive STAT3-mediated self-renewal of glioma stem-like cells through secretion-mediated signaling. The result is a tumor in which STAT3 remains lit even when the receptor at the top of the pathway has been chemically silenced.

This non-canonical, microenvironment-driven STAT3 activation has profound consequences for every pillar of current glioblastoma therapy. The review systematically lays out how persistent STAT3 signaling promotes glioma stemness, the maintenance of a self-renewing population of tumor-initiating cells that are notoriously resistant to both chemotherapy and radiotherapy. It also describes how STAT3 drives metabolic reprogramming, allowing tumor cells to adapt their energy metabolism to the nutrient-poor, oxygen-starved conditions of the tumor core. Perhaps most strikingly, STAT3 activity shapes the immune landscape of the tumor, fostering immune suppression and immune evasion that undermine both endogenous antitumor immunity and emerging immunotherapeutic approaches. In other words, STAT3 is not merely a backup signal; it is a master regulator of the resistant state that glioblastoma adopts under therapeutic pressure.

The clinical record bears out this mechanistic picture. The review recounts a series of high-profile failures in EGFR-directed therapy for glioblastoma, including trials of tyrosine kinase inhibitors such as erlotinib and osimertinib, the EGFR-targeted antibody-drug conjugate depatuxizumab mafodotin in EGFR-amplified newly diagnosed disease, and the EGFRvIII vaccine rindopepimut in relapsed tumors expressing that mutation. In each case, the molecular rationale was sound, and in each case the tumor found a way around the blockade. Recent work cited in the review has shown that resistance to EGFR antibody-drug conjugates is driven by transcriptional reprogramming and TEK-induced EGFR suppression, further illustrating that the tumor’s escape routes extend beyond simple pathway reactivation. What unites these observations is the emerging consensus that compensatory signaling, with STAT3 as a critical node, allows glioblastoma to survive targeted attack.

Importantly, the review does not treat this as a purely glioblastoma-specific problem. The authors draw on evidence from other cancers, including lung and colorectal tumors, where feedback activation of STAT3 has been documented as a general drug-resistance mechanism following EGFR inhibition. Clinical trials in EGFR-mutant lung cancer have tested combinations of EGFR inhibitors with JAK inhibitors such as ruxolitinib and momelotinib, providing proof of concept that dual blockade of the axis is feasible in patients. This cross-cancer perspective strengthens the argument that the EGFR–STAT3 crosstalk is a fundamental property of oncogene-addicted tumors rather than an idiosyncrasy of brain cancer, and it suggests that lessons learned in other tumor types could be translated to glioblastoma, provided the unique challenges of the blood–brain barrier are addressed.

That barrier is one of the practical obstacles the review confronts head-on. Delivering signaling inhibitors to the brain remains notoriously difficult, and the authors discuss drug-delivery innovations designed to overcome it, including sustained-release hydrogel systems engineered to deliver the JAK inhibitor ruxolitinib directly to glioma tissue. Preclinical studies have shown that ruxolitinib can enhance the cytotoxic and apoptotic effects of temozolomide on glioblastoma cells, and that EGFR blockade in glioblastoma brain tumor stem cells synergizes with JAK2/STAT3 pathway inhibition to abrogate the compensatory mechanisms that otherwise allow the stem-cell compartment to survive. These findings point toward a therapeutic logic of vertical and horizontal pathway suppression: hitting EGFR and STAT3 simultaneously, rather than sequentially, so that the tumor has no intact escape route left to exploit.

The review also surveys a broader arsenal of strategies aimed at the axis. Dual-target inhibitors that engage both EGFR and JAK3 have been developed and shown to overcome resistance driven by KRAS mutations in colorectal cancer, offering a template for similar agents in glioblastoma. Natural-product-derived compounds, including resveratrol, have been reported to enhance temozolomide efficacy by downregulating MGMT and inactivating STAT3 through its negative regulators, and to ameliorate the inflammatory tumor response by suppressing NLRP3 inflammasome activation via the JAK2/STAT3 pathway. Pyrimidine compounds such as BY4003 and BY4008 have been shown to inhibit glioblastoma cell growth by modulating JAK3/STAT3 signaling. Exosome-based approaches, including circPRKD3-loaded extracellular vesicles that inhibit STAT3 signaling while simultaneously remodeling the tumor microenvironment, represent a nanoscale delivery strategy that targets both the tumor cells and their supporting stroma. Each of these approaches attacks a different face of the same adaptive hub.

The immunological dimension of STAT3 inhibition deserves particular emphasis, because it may determine whether the next generation of glioblastoma therapy succeeds where checkpoint blockade has failed. STAT3 is a central regulator of the immunosuppressive glioblastoma microenvironment, shaping the behavior of tumor-associated macrophages, microglia, and regulatory T cells. Preclinical work has shown that combining radiation with STAT3 blockade triggers dendritic cell–T cell interactions in the glioma microenvironment and improves therapeutic efficacy, suggesting that STAT3 inhibition could convert a immunologically cold tumor into one that responds to immunotherapy. Given the disappointing results of anti-PD-1 and anti-PD-L1 agents as monotherapy in glioblastoma, the prospect of using axis-targeted therapy to prime the immune system represents one of the most compelling rationales for pursuing this strategy in the clinic.

What emerges from this comprehensive synthesis is a reframing of the glioblastoma problem. The tumor is not simply an EGFR-driven cancer that has eluded EGFR drugs; it is an adaptively resistant ecosystem in which the EGFR–STAT3 axis functions as the integrating hub of survival under stress. The authors’ systematic dissection of the molecular mechanisms underlying EGFR–STAT3 crosstalk, their attention to non-canonical and microenvironment-driven STAT3 activation, and their honest accounting of past therapeutic failures together build a case that future trials must be designed around combination strategies that close the escape routes before they open. No clinical data yet confirm that dual EGFR–STAT3 blockade will improve outcomes for glioblastoma patients, and the review is careful to frame its conclusions as a proposal grounded in accumulating evidence rather than a proven treatment paradigm. But the logic is clear and the preclinical foundation is strengthening: to break adaptive oncogenic resistance in one of medicine’s most lethal cancers, the field may need to stop attacking single nodes and start disabling the entire rewired network at once.

Subject of Research: Adaptive resistance mechanisms mediated by the EGFR–STAT3 signaling axis in glioblastoma

Article Title: Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR–STAT3 axis

Article References: Ahmad, N., & Ullah, A. (2026). Breaking adaptive oncogenic resistance in glioblastoma via targeting the EGFR–STAT3 axis. Medical Oncology, 43(11), Article 327. https://doi.org/10.1007/s12032-026-03459-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03459-4

Keywords: glioblastoma, EGFR, STAT3, JAK/STAT pathway, adaptive resistance, targeted therapy, tumor microenvironment, glioma stem cells, immunosuppression, temozolomide, drug resistance, brain tumor

The biological rationale behind the combination rests on a concept oncologists call synthetic lethality. PARP enzymes are central to the base excision repair pathway, the cellular machinery that patches up single-strand breaks in DNA, which arise constantly from normal metabolic activity and environmental insults. When PARP is inhibited, these single-strand breaks accumulate and can collapse replication forks during cell division, converting them into far more dangerous double-strand breaks. Temozolomide, meanwhile, is an alkylating agent that methylates DNA, overwhelming the cell with lesions that require repair. By blocking PARP while simultaneously flooding the genome with methylation damage, the combination creates a scenario in which cancer cells are battered from two directions at once, while relatively healthy cells, with intact complementary repair pathways, can often survive the assault. This logic has already proven successful in BRCA-mutated ovarian and breast cancers, and small-cell lung cancer, with its characteristic genomic instability and high mutational burden, has long been considered a plausible candidate for a similar approach.

The trial, registered as NCT05728619, enrolled 59 patients between February 2023 and November 2023. All participants had relapsed ES-SCLC and had received either one or two prior lines of therapy, placing them squarely in the population where options are scarcest. The study was structured in two parts. The phase Ib portion used a classic 3+3 dose-escalation design to identify the recommended phase II dose (RP2D) of HTMC0435, while temozolomide was administered at a fixed dose of 75 milligrams per square meter of body surface area on days 1 through 7 of each 21-day cycle. Patients continued treatment until their disease progressed or side effects became intolerable. The primary endpoints were dose-limiting toxicity, maximum tolerated dose, the RP2D itself, and adverse events, with efficacy measures tracked as secondary outcomes.

One of the most striking technical findings of the dose-escalation phase was what did not happen: no dose-limiting toxicities occurred at all. In a 3+3 design, dose-limiting toxicity is the safety signal that halts escalation and defines the maximum tolerated dose, so its complete absence meant that the maximum tolerated dose could not be formally determined within the dose range explored. Instead, the investigators selected 8 milligrams of HTMC0435 taken twice daily as the recommended phase II dose, a decision that speaks to both the tolerability of the agent at the doses tested and the pragmatic realities of early-phase trial design when toxicity signals fail to materialize. Fifty-five patients, three from the phase Ib portion and 52 from the phase II expansion, went on to receive the combination at this recommended dose.

The safety profile, while not benign, was characterized as manageable. Grade 3 or 4 treatment-related adverse events, the severe toxicities that clinicians monitor most closely, occurred in 33 of the 59 patients, representing 55.9 percent of the enrolled population. The dominant toxicities were hematologic, meaning they affected blood cell production in the bone marrow. Neutropenia, a depletion of the infection-fighting white blood cells known as neutrophils, was the most common, affecting 23 patients or 39.0 percent. Leukopenia, a broader reduction in white blood cells, affected 18 patients, or 30.5 percent. These patterns are consistent with the known myelosuppressive effects of both temozolomide and PARP inhibition, since rapidly dividing bone marrow progenitors are particularly vulnerable to DNA-damaging and DNA repair-blocking agents. Critically, however, no treatment-related deaths occurred, a fact that the investigators highlight as evidence that the regimen’s risks can be monitored and managed in a clinical setting.

On the efficacy front, the results offered genuine grounds for cautious optimism in a disease where second-line response rates with standard chemotherapy are historically dismal. Among the 48 patients whose tumors could be formally evaluated for response, the objective response rate, meaning the proportion whose tumors shrank measurably, was 25.0 percent, with 12 of 48 patients responding. The 95 percent confidence interval ranged from 13.6 to 39.6 percent, a wide band that reflects the modest sample size but still sits well above what single-agent temozolomide typically achieves in this setting. Perhaps most notably, median overall survival across all 55 treated patients reached 11.2 months, with a confidence interval of 8.97 to 13.14 months. For a relapsed extensive-stage population, where median survival on second-line therapy has historically hovered in the range of only a few months, a double-digit median overall survival figure is a result that will command attention.

Equally intriguing was the observation that the benefit appeared to extend across both major clinical subgroups of relapsed disease. Patients were categorized as platinum-sensitive if they had gone at least 90 days without chemotherapy before relapse, and platinum-resistant if their chemotherapy-free interval was shorter than 90 days. This distinction matters enormously in small-cell lung cancer, because platinum-based regimens such as etoposide plus cisplatin or carboplatin produce high initial response rates, but tumors that recur quickly after platinum exposure are notoriously refractory to further platinum treatment. The trial reported similar trends of benefit in both the platinum-sensitive and platinum-resistant groups, suggesting that the PARP inhibitor and temozolomide combination may work through mechanisms that do not depend on residual platinum sensitivity. If confirmed, this would be particularly valuable for platinum-resistant patients, who currently have the fewest options and the worst prognoses.

The study also incorporated biomarker analysis, reflecting a growing consensus that the future of PARP inhibitor development depends on identifying which patients are most likely to respond. Small-cell lung cancer is defined in part by near-universal loss of functional TP53 and RB1 tumor suppressors, and its genomic instability creates a tumor biology that may be especially dependent on PARP-mediated repair. The biomarker work in this trial, which examined single nucleotide variants in tumor samples, represents an early step toward building a predictive framework, though the investigators acknowledge that the sample size limits definitive conclusions. Larger randomized studies with prospective biomarker stratification will be needed to determine whether specific genomic features can identify the subset of patients who derive the greatest benefit from the combination.

The trial was led by a team at Zhejiang Cancer Hospital in Hangzhou, with corresponding authors Zhiyu Huang and Yun Fan, and involved collaborating centers in Jiangsu, Henan, Hubei, and Shandong provinces. It was funded by the National Natural Science Foundation of China and by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., the company developing HTMC0435, with one co-author employed by the sponsor. The investigators are careful in their conclusions: the combination showed a manageable safety profile and initial indications of anti-tumor activity in recurrent ES-SCLC, but further validation in randomized controlled trials is required. That caveat is well founded. Single-arm phase II trials are vulnerable to selection bias, and historical comparisons across different trials can be misleading in a disease as heterogeneous as small-cell lung cancer.

Nevertheless, the trial adds momentum to a broader renaissance in small-cell lung cancer research. After decades in which the disease was treated with essentially the same platinum-doublet chemotherapy first established in the 1980s, the past several years have seen immunotherapy reshape first-line treatment, and now DNA damage response inhibitors are being tested as a strategy for the relapsed setting. Multiple PARP inhibitors and related agents targeting DNA repair enzymes, including ATM and ATR inhibitors, are in clinical development for this indication. The HTMC0435 and temozolomide data provide one of the more concrete signals to date that this approach can deliver meaningful survival in heavily pretreated patients. For the roughly two-thirds of small-cell lung cancer patients who present with extensive-stage disease, and for the majority of those who eventually relapse, the prospect of an oral, outpatient regimen with a defined toxicity profile and a double-digit survival median represents a genuine step forward. The next test will come in randomized trials, where the combination must prove that the survival signal observed here holds up against current standards of care.

Subject of Research: A phase Ib/II trial of the PARP inhibitor HTMC0435 combined with temozolomide in relapsed extensive-stage small-cell lung cancer

Article Title: Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trial

Article References: Yu, S., Gong, L., Qian, J., Zhao, Y., Chen, K., Li, H., Xu, Y., Han, G., Meng, X., Qin, J., Lu, H., Han, N., Gu, C., Cheng, Y., Huang, Z., & Fan, Y. (2026). Safety, efficacy, and biomarker analysis of HTMC0435 plus temozolomide in relapsed extensive-stage small-cell lung cancer: A phase Ib/II trial. BMC Medicine. https://doi.org/10.1186/s12916-026-05292-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05292-y

Keywords: small-cell lung cancer, PARP inhibitor, HTMC0435, temozolomide, clinical trial, phase Ib/II, DNA repair, chemotherapy, platinum-resistant, biomarkers, oncology, BMC Medicine

Lymphocytes, the white blood cells that include T cells, B cells, and natural killer cells, are the sentinels of the adaptive immune system. They are also among the most radiosensitive cells in the human body. Unlike most tissues, however, lymphocytes do not sit still in one place during a course of radiotherapy. They circulate continuously through the bloodstream, which means that during brain irradiation, a substantial fraction of the body’s entire lymphocyte pool passes through the irradiated volume and is destroyed as it transits the treatment field. This mechanism, first modeled in detail by researchers at Johns Hopkins more than a decade ago, explains why even highly conformal modern radiotherapy can inflict significant collateral damage on the immune system.

The clinical stakes are considerable. Multiple studies, including a 2024 systematic review and pooled analysis, have found that patients who develop severe lymphopenia during chemoradiotherapy for glioblastoma survive substantially shorter periods than those who maintain their lymphocyte counts. Some investigators have proposed that radiation-induced immune depletion may blunt any potential benefit of immunotherapy in these patients and may even impair the body’s intrinsic ability to control residual tumor cells. What has remained contentious is precisely which dosimetric parameters best predict the severity of lymphocyte loss, and whether the culprit is the volume of brain irradiated, the dose delivered, or simply the size of the tumor target itself.

To address this question, Paolo Tini and colleagues conducted a retrospective single-center cohort study of 102 adults with histologically confirmed IDH-wildtype glioblastoma, the most common and aggressive molecular subtype of the disease. All patients had paired blood counts taken before radiotherapy and at treatment completion, along with detailed dose-volume histogram data for the whole brain and precise measurements of their target volumes—the gross tumor volume, clinical target volume, and planning target volume. The researchers also accounted for a battery of potential confounders, including baseline lymphocyte count, corticosteroid exposure, temozolomide administration, infection, and the number of radiation fractions delivered.

The results were striking. Median absolute lymphocyte counts fell from 1,810 cells per microliter before treatment to 1,050 cells per microliter at the end of radiotherapy, a median relative decline of 42.6 percent. Clinically significant lymphopenia was common: 32.4 percent of patients developed grade 2 or worse lymphopenia according to the Common Terminology Criteria for Adverse Events, and 13.7 percent developed grade 3 or worse. These figures underscore that immune depletion is not a rare toxicity but a near-universal feature of standard glioblastoma chemoradiotherapy, occurring in roughly one in three patients at a severity level that clinicians would typically flag as clinically meaningful.

The dosimetric analysis revealed a coherent and consistent pattern. In multivariable robust linear regression models adjusted for baseline lymphocyte count and major confounders, several measures of cerebral dose burden independently predicted lower lymphocyte counts at the end of treatment. Mean brain dose showed a significant association, with each additional 5 Gy reducing the log-transformed lymphocyte count by a factor corresponding to a beta coefficient of −0.251. The volume of brain receiving 15, 20, and 25 Gy—often abbreviated V15Gy, V20Gy, and V25Gy—each showed significant associations, as did the integral dose, a metric that captures the total energy deposited in the brain. Notably, V10Gy was also significant, while V5Gy was not, suggesting that intermediate-dose exposure in the range of roughly 15 to 25 Gy represents the most consistent dosimetric signal.

Perhaps the most provocative finding concerns the relationship between target volume and lymphocyte depletion. The planning target volume was strongly correlated with V20Gy, with a Spearman correlation coefficient of 0.78, meaning that larger targets inevitably expose more brain to intermediate doses. Yet when the researchers examined the direct association between target volume and lymphocyte preservation, it was negligible—a correlation of just −0.06, with a p-value of 0.55 indicating no statistically meaningful relationship. In other words, target size alone does not explain the immune damage. Two patients with similarly sized tumors could experience very different degrees of lymphocyte depletion depending on how the radiation dose is distributed through the surrounding brain, a conclusion that carries immediate implications for treatment planning.

The prognostic implications were equally clear. Using a landmark analysis anchored at the completion of radiotherapy—a design that avoids the statistical pitfalls of immortal time bias—the researchers found that grade 2 or worse lymphopenia was independently associated with inferior overall survival, with a hazard ratio of 2.43, and inferior progression-free survival, with a hazard ratio of 2.42. Patients whose immune systems were depleted during treatment faced more than double the risk of death and disease progression compared with those who preserved their lymphocyte counts, even after adjustment for other clinical and molecular variables. While the retrospective design of the study means that causality cannot be definitively established—lymphopenia could theoretically be a marker of some other adverse factor—the consistency of the association across multiple independent cohorts lends considerable weight to the biological interpretation.

The findings arrive at a moment when the field of radiation oncology is increasingly attentive to the immunological consequences of treatment. Prior work has shown that reducing the radiation treatment volume can lessen lymphopenia, and a randomized phase II study has demonstrated that proton therapy, which deposits less exit dose in normal tissue, reduces the likelihood of high-grade radiation-induced lymphopenia compared with conventional photon therapy. Other investigations have explored the role of intensity-modulated radiotherapy techniques and even the dose delivered to brain vasculature through which lymphocytes traffic. The Siena study adds an important nuance to this conversation: it is not enough to shrink the target or switch particle types. Planners must actively attend to the dose bath delivered to the otherwise healthy brain, particularly the intermediate-dose region between 15 and 25 Gy.

The authors argue that their findings support the prospective evaluation of immune-sparing radiotherapy strategies that reduce unnecessary cerebral dose exposure without compromising coverage of the tumor target. Such strategies might include tighter conformality, dose-escalation constraints on the normal brain, proton therapy in selected cases, or modified fractionation schedules. Given that glioblastoma remains one of the deadliest human cancers, with median survival measured in months despite aggressive multimodal treatment, any intervention that could preserve immune function without sacrificing tumor control deserves rigorous testing. This study, conducted without external funding and approved by the local ethics committee, offers a compelling dosimetric roadmap for that effort—and a reminder that in the quest to kill tumor cells, the collateral cost to the immune system may be a modifiable determinant of how long patients live.

Subject of Research: The association between cerebral radiation dose burden, treatment-related lymphopenia, and survival in IDH-wildtype glioblastoma

Article Title: Brain dose burden is associated with treatment-related lymphopenia in IDH-wildtype glioblastoma: dosimetric determinants and prognostic impact

Article References: Tini, P., Donnini, F., Battaglia, G., Pastina, P., Rubino, G., Carfagno, T., Vannini, M., Didona, A., Vanzi, E., & Banci Buonamici, F. (2026). Brain dose burden is associated with treatment-related lymphopenia in IDH-wildtype glioblastoma: dosimetric determinants and prognostic impact. Journal of Neuro-Oncology, 179(2), Article 81. https://doi.org/10.1007/s11060-026-05801-2

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05801-2

Keywords: glioblastoma, lymphopenia, radiotherapy, brain dosimetry, V20Gy, integral dose, mean brain dose, temozolomide, immune-sparing radiotherapy, proton therapy, overall survival, IDH-wildtype

The story begins in the 1970s, when the RTOG Brain Tumor Committee emerged in the wake of the seminal Brain Tumor Study Group trials to prospectively evaluate new strategies for CNS malignancies. Early protocols tackled the most basic questions: how much radiation should be delivered, to what volume, and in how many fractions. These studies established foundational paradigms, including the biphasic 60 Gy approach for glioblastoma, in which 46 Gy is delivered to a larger target volume followed by a 14 Gy boost, and demonstrated the feasibility of combining radiation with nitrosourea chemotherapy. Just as importantly, they revealed a sobering truth that would steer the field for decades: pushing radiation doses higher and intensifying schedules was technically achievable but did not translate into longer survival, and it frequently increased toxicity. Randomized phase I and II studies of hyperfractionated and accelerated regimens, fast neutrons, and hypoxic-cell and S-phase sensitizers collectively established the limits of radiotherapy intensification in malignant gliomas.

That negative finding proved generative rather than deflating. It spawned three hypotheses that still animate research today: that gliomas harbor innate radioresistance, later attributed in part to stem-like cells; that legacy imaging inadequately targets microscopic disease, catalyzing advanced imaging-based targeting; and that combinatorial approaches are needed to eradicate disease lurking outside the radiation field. It also redirected the group toward methodological refinement. Large accumulated datasets enabled the creation of prognostic tools such as the recursive partitioning analysis, or RPA, classification, which stratified patients by expected outcome and became a standard stratification variable. A series of highly efficient single-arm phase II trials harnessed historical data for comparison, minimizing the number of control patients required and predating the modern concept of synthetic control arms. Agents such as the hypoxic-cell toxin tirapazamine and anti-angiogenic thalidomide were screened in this disciplined framework; most failed to justify phase III testing, but the triage system itself became a durable cooperative-group asset.

The molecular era arrived through some of the group’s most consequential work. Long-term follow-up of RTOG 94-02, a trial first launched in the 1990s that added procarbazine, lomustine, and vincristine, known as PCV chemotherapy, to radiotherapy for anaplastic oligodendroglial tumors, demonstrated that patients whose tumors carried both the 1p/19q co-deletion and an IDH mutation, now classified as grade 3 oligodendroglioma, saw their survival roughly doubled by PCV. Patients with IDH-mutant but non-co-deleted tumors, now called grade 3 astrocytoma, benefited less dramatically, while those with IDH-wildtype disease, now termed molecular glioblastoma, gained nothing. This was among the earliest prospective validations of molecularly informed treatment benefit in neuro-oncology, and it directly influenced subsequent tumor classification systems and trial eligibility paradigms. The companion trial RTOG 9402, together with its European counterpart, cemented PCV plus radiotherapy as a categorical standard for these tumors, even as temozolomide was being adopted broadly across all glioma grades on thinner evidence, prompting definitive head-to-head testing through the CODEL trial.

Glioblastoma itself proved a harder nut to crack, and the trial record is a study in disciplined negative results. After the EORTC and NCI-Canada trial established temozolomide-based chemoradiation as the standard for glioblastoma, RTOG 9813 extended temozolomide to anaplastic astrocytoma, finding no overall survival advantage over nitrosourea but a more favorable toxicity profile, effectively making temozolomide the standard, with post-hoc analysis identifying IDH mutation as both a prognostic and predictive biomarker. RTOG 0525 then showed that dose-dense temozolomide improved neither survival nor progression-free survival and carried higher toxicity, measured with a battery of neurocognitive, symptom, and quality-of-life tests. RTOG 0825 tested the addition of the anti-angiogenic antibody bevacizumab to standard chemoradiation and found no survival benefit despite longer progression-free survival, along with worse patient-reported outcomes and cognitive decline over time. NRG-BN011 could not reproduce the survival benefit of combined temozolomide and lomustine seen in a smaller German trial. Each disappointment sharpened the field’s appreciation that functional endpoints, not just survival curves, must anchor brain tumor research.

Not every modern effort has come up short. RTOG/NRG 1205, reported in 2023, provided the first high-level evidence supporting re-irradiation in recurrent glioblastoma, showing that adding radiation to bevacizumab significantly improved progression-free survival compared with bevacizumab alone in a disease where median survival after recurrence hovers at six to nine months. On the technology frontier, NRG-BN001, a signal-seeking randomized phase II study, met its overall survival endpoint for dose-escalated proton therapy to 75 Gy, and a definitive phase III trial is now in development. NRG-BN005 has completed accrual comparing proton with photon therapy in IDH-mutant lower-grade gliomas with cognitive preservation as its primary focus, and a newly launched study, NRG-CC017, is testing temporally modulated pulsed reduced dose-rate radiotherapy for neurofunctional preservation in glioblastoma. Biomarker-selected trials, including RTOG 0627 of dasatinib in target-selected recurrent glioblastoma, RTOG Foundation Study 3508 of the EGFR-targeted antibody-drug conjugate depatuxizumab mafodotin, and NRG-BN007 of dual checkpoint inhibition in MGMT-unmethylated tumors, illustrate the steady shift toward biology-guided designs.

In brain metastases, the group’s trials arguably transformed practice most visibly. Early studies fixed whole brain radiotherapy schedules of 30 Gy in 10 fractions and 37.5 Gy in 15 fractions as standards, but subsequent attempts at dose escalation, altered fractionation, and radiosensitization yielded no survival gains. RTOG 9508 then inaugurated the stereotactic radiosurgery era, and subsequent randomized work established radiosurgery alone as a standard that preserves neurocognitive function without compromising survival for many patients with limited metastases. Ongoing studies now push the paradigm further, including a trial of radiosurgery for up to 15 brain metastases, a comparison of radiosurgery against hippocampal-avoidance whole brain radiotherapy in small cell lung cancer, and NRG-BN013’s formal test of single versus fractionated radiosurgery for larger lesions. On the spine, RTOG 0631 found no clinical benefit for single-fraction stereotactic body radiotherapy over conventional radiotherapy for localized metastases, a reminder that precision techniques must earn their place.

Perhaps the most patient-centered triumph is the neuroprotection portfolio. RTOG 0614 demonstrated that the NMDA receptor antagonist memantine could delay cognitive decline after whole brain radiotherapy, the first prospective evidence of pharmacologic neuroprotection in this setting. Building on the insight that the hippocampal neural stem-cell niche repopulates the cells subserving memory, the group developed hippocampal-avoidance techniques and validated them in NRG-CC001, a randomized phase III trial showing a significant reduction in cognitive failure when hippocampal-avoidance whole brain radiotherapy was combined with memantine. Crucially, the achievement was as much infrastructural as scientific: standardized contouring atlases, credentialing processes, real-time centralized plan review, and widespread educational programs trained large numbers of radiation oncologists in consistent hippocampal-sparing, enabling rapid adoption into routine practice. The strategy is now extending to prophylactic cranial irradiation in small cell lung cancer through NRG-CC003, and to leptomeningeal disease, where a recent randomized phase II trial showed that proton craniospinal irradiation significantly improved progression-free and overall survival, with the definitive NRG-BN014 trial underway.

The review also documents quieter but meaningful advances in meningioma and primary CNS lymphoma. RTOG 0539 pioneered risk-stratified, prospective radiotherapy for meningioma, demonstrating excellent progression-free survival in intermediate-risk patients treated after surgery, and its infrastructure of centralized imaging review and protocol-driven delivery has spun off a portfolio of trials incorporating molecular imaging with DOTATATE-PET and even a radioligand therapeutic, lutetium-177 DOTATATE, for recurrent high-risk disease. In primary CNS lymphoma, RTOG 1114 showed that reduced-dose whole brain radiotherapy added to R-MPV-A chemoimmunotherapy significantly improved progression-free survival, exemplifying response-adapted radiotherapy that balances disease control against neurotoxicity. The authors distill the lessons into a roadmap: enrich patient selection with molecular profiling, choose realistic endpoints, plan accrual conservatively, recognize barriers in de-escalation trials, insist on central pathology and real-time radiotherapy quality review, and keep trials patient-centric. Taken together, fifty years of cooperative group science trace a clear arc, from empiric dose-finding to precision, biology-informed, and cognitively protective care, and they suggest that the collaborative trial network remains the indispensable engine for the next generation of brain tumor breakthroughs.

Subject of Research: Evolution of cooperative group clinical trials for central nervous system tumors by RTOG and NRG Oncology

Article Title: The evolution of RTOG and NRG Oncology CNS tumors clinical trials

Article References: Sehrawat, K., Polley, M.-Y. C., Vogelbaum, M. A., Gilbert, M., Chakravarti, A., Cahill, D. P., Lassman, A. B., Raleigh, D. R., Sulman, E. P., Machtay, M., Le, Q. T., Curran, W., Gondi, V., & Mehta, M. P. (2026). The evolution of RTOG and NRG Oncology CNS tumors clinical trials. Journal of Neuro-Oncology, 179(2), Article 83. https://doi.org/10.1007/s11060-026-05788-w

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05788-w

Keywords: RTOG, NRG Oncology, CNS tumors, glioblastoma, brain metastases, stereotactic radiosurgery, hippocampal-avoidance radiotherapy, temozolomide, PCV chemotherapy, primary CNS lymphoma, meningioma, clinical trials

The core problem is delivery. The blood–brain barrier, a tightly packed layer of endothelial cells lining the brain’s blood vessels, blocks more than 98 percent of small-molecule drugs and virtually all large molecules. In glioblastoma, a second obstacle appears: the blood–brain–tumor barrier, which is patchy and inconsistent, leaving large regions of the tumor effectively unreachable. Even where drugs do penetrate, elevated interstitial fluid pressure inside the tumor pushes fluid—and anything dissolved in it—back toward healthy tissue, while a dense extracellular matrix physically impedes the diffusion of nanoparticles. Efflux pumps such as P-glycoprotein actively expel chemotherapy agents that manage to enter tumor cells. The result is that standard-of-care temozolomide, the oral alkylating agent given after surgery and radiotherapy, reaches only a fraction of the tumor mass, and the disease almost invariably recurs.

The review’s central argument is that these barriers can be turned into an advantage by exploiting a molecular quirk of glioblastoma cells: they overexpress folate receptors. These receptors, normally responsible for capturing vitamin B9 from the bloodstream, sit on the cell surface and bind folic acid with extraordinarily high affinity. Crucially, folate receptor uptake occurs through receptor-mediated endocytosis, a process in which the cell literally swallows anything attached to the ligand. By chemically grafting folic acid onto the surface of a nanoparticle, researchers create a vehicle that tumor cells actively pull inside themselves. Because folate receptors are largely absent from most healthy adult tissues, the strategy offers a built-in selectivity mechanism that conventional chemotherapy lacks entirely.

The chemistry behind this targeting is more sophisticated than simply sticking a vitamin onto a particle. The review describes two principal conjugation routes. Direct ligand coupling attaches folic acid straight to functional groups on the nanoparticle surface, typically through the gamma carboxyl group of glutamate, which preserves the vitamin’s binding face for the receptor. Linker-assisted surface modification, by contrast, uses spacer molecules—often polyethylene glycol—to project the folate ligand away from the particle surface, reducing steric hindrance and improving receptor engagement. Common coupling reagents include carbodiimide chemistry such as EDC and NHS esters, which form stable amide bonds between the folate and amine- or carboxyl-bearing polymer surfaces. The length and flexibility of these linkers matter enormously: a folate buried against the particle surface may never contact its receptor, while one tethered on a sufficiently long spacer can bind even when the particle itself is too bulky to approach the membrane closely.

The nanocarriers themselves span a remarkable range of materials. Poly(lactic-co-glycolic acid), or PLGA, a biodegradable polymer approved by regulators for other uses, can encapsulate hydrophobic drugs and release them slowly as it erodes. Liposomes, spherical vesicles built from phospholipid bilayers, carry both water-soluble and lipid-soluble payloads. Human serum albumin nanoparticles, magnetic iron oxide particles known as SPIONs, quantum dots, carbon nanotubes, and boron nitride nanotubes have all been folate-functionalized in experimental studies. Each platform brings its own theranostic capability: SPIONs serve as magnetic resonance imaging contrast agents and can generate heat under alternating magnetic fields for magnetic hyperthermia, while quantum dots and near-infrared dyes such as IR-780 enable fluorescence imaging that can guide surgical resection or monitor treatment response in real time.

Preclinical evidence reviewed by the authors suggests the strategy delivers measurable gains. In rat models of glioma, temozolomide loaded into folate-conjugated magnetic triblock copolymer nanoparticles improved therapeutic outcomes compared with free drug, with the magnetic component additionally enabling image-guided delivery and hyperthermia sensitization. Folate-targeted erlotinib, an epidermal growth factor receptor inhibitor, delivered in human serum albumin nanoparticles reduced tumor size and extended survival in glioblastoma-bearing rats. Liposomal formulations carrying combinations of temozolomide and the antimalarial artesunate have shown activity against drug-resistant tumors, while folate-modified lipid–polymer hybrid nanoparticles have improved paclitaxel delivery to intracranial disease. Dual-targeting systems that pair folate with glucose or other brain-shuttle ligands aim to solve the two-stage problem—first crossing the blood–brain barrier, then engaging tumor cells—by combining a transcytosis trigger with a receptor-homing ligand on the same particle.

The theranostic concept is what distinguishes these systems from ordinary targeted drug delivery. A single nanoparticle can simultaneously carry a chemotherapeutic payload, an imaging agent, and sometimes a physical therapy modality such as photothermal or photodynamic activation. This integration means clinicians could, in principle, visualize exactly where a drug has accumulated before and during treatment, adjusting dosing on the basis of real-time tumor mapping rather than population averages. For a disease like glioblastoma, where surgical margins are notoriously ambiguous and response assessment with conventional MRI is complicated by treatment-related changes that mimic progression, the diagnostic half of the theranostic pair could be as valuable as the therapeutic half.

Safety, however, remains the field’s unresolved question. The review notes that folate-armed nanotheranostics have so far shown good biocompatibility and low systemic toxicity in experimental settings, a benefit attributed partly to the reduced off-target exposure that receptor targeting provides. Yet the authors are explicit that long-term safety has not been established. Nanoparticles can persist in organs of the reticuloendothelial system, accumulate in the liver and spleen, and interact with the protein corona that forms on their surfaces in blood—a layer of adsorbed proteins that can alter both targeting behavior and immune recognition. Degradation products of some nanomaterials raise their own toxicological concerns, and the behavior of these particles over years rather than weeks is essentially unknown. Translating encouraging rodent data into human trials will require answering these questions systematically.

There are also biological caveats. Folate receptor expression varies between patients and even between regions of the same tumor, meaning a folate-targeted therapy could miss receptor-negative cell populations and select for resistant clones. The reduced folate carrier, an alternative folate transport pathway, complicates the targeting picture in some tissues. And the fundamental delivery problem of crossing an intact blood–brain barrier has not vanished; folate targeting addresses the tumor-cell engagement step far better than the barrier-crossing step, which is why combination strategies and convection-enhanced delivery techniques continue to be explored alongside receptor targeting.

Even with these caveats, the convergence of folate chemistry, nanomaterial engineering, and imaging technology represents a genuinely integrated response to a disease that has defeated nearly every conventional approach. The review by Bari and Pardeshi consolidates a decade and a half of work—from the foundational demonstration that folate receptors could be exploited for tumor imaging and drug delivery, through the structural determination of how folic acid is recognized by its receptor, to the current generation of multifunctional, dual-targeted, image-guided platforms. No folate-armed nanotheranostic has yet completed clinical development for glioblastoma, and the gap between mouse and human brain remains wide. But the logic of the approach—turning the tumor’s own appetite for folate into a delivery mechanism that carries both medicine and a camera—offers something glioblastoma patients have rarely had: a way to see the target and hit it at the same time. Whether that promise survives the long road of safety testing and clinical validation will be one of the more consequential stories in neuro-oncology over the coming decade.

Subject of Research: Folate-conjugated nanotheranostic platforms for targeted diagnosis and treatment of glioblastoma

Article Title: Nanotheranostics armed with folate: an integrated approach for precision targeting of glioblastoma

Article References: Bari, D. B., & Pardeshi, C. V. (2026). Nanotheranostics armed with folate: an integrated approach for precision targeting of glioblastoma. Medical Oncology, 43(10), Article 283. https://doi.org/10.1007/s12032-026-03363-x

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03363-x

Keywords: glioblastoma, nanotheranostics, folate receptors, blood–brain barrier, drug delivery, nanoparticles, temozolomide, targeted therapy, brain cancer, theranostics, nanomedicine, molecular imaging

The biology behind the measurement is central to why this matters. MGMT encodes O6-methylguanine–DNA methyltransferase, a repair enzyme that directly reverses the kind of DNA damage temozolomide inflicts. When the gene’s promoter is silenced by methylation — the addition of methyl groups to CpG dinucleotides in the regulatory region — tumor cells produce little of the repair protein and remain vulnerable to the drug. Methylation of the promoter is therefore a predictive biomarker: patients whose tumors are hypermethylated derive greater benefit from temozolomide, showing improved progression-free and overall survival, while those with unmethylated tumors respond poorly. In the study’s large molecular cohort, tumors classified as hypermethylated at the first time point carried a mean methylation percentage of 35.6 percent, ranging up to 89 percent, whereas unmethylated tumors averaged just 2.1 percent — a wide biological gulf that the binary labels tend to conceal.

To interrogate how that gulf behaves over the course of disease, the researchers, led by Henry Noren and Morana Vojnic of Rutgers Cancer Institute and collaborating institutions, turned to a large commercial molecular profiling database maintained by Caris Life Sciences. They identified patients with recurrent glioma who had undergone molecular testing at two distinct time points and, after excluding cases with insufficient tissue, assembled 426 paired samples. MGMT promoter methylation was assessed by pyrosequencing of CpG sites 74 through 78, following bisulfite conversion of DNA extracted from formalin-fixed paraffin-embedded tissue with at least 50 percent tumor nuclei. The laboratory reported both a quantitative methylation percentage and a categorical status: hypermethylated at 9 percent or above, equivocal between 7 and under 9 percent, and unmethylated below 7 percent. Equivocal cases were assigned to the unmethylated group for analysis, in line with prior studies.

The headline finding is strikingly simple. In 84 percent of tumors — 358 of 426 — the categorical MGMT status was identical at diagnosis and at recurrence, with 52 percent remaining unmethylated and 32 percent remaining hypermethylated. Only 16 percent changed status, and the direction of change was uneven: 11 percent shifted from hypermethylated to unmethylated, while just 5 percent gained hypermethylation. More importantly, when the researchers examined the underlying quantitative values, the average change in methylation percentage across the whole cohort was a modest minus 1.4 percentage points, with a standard deviation of 16.0. Tumors that kept their original classification barely moved at all, drifting by only minus 0.3 points in the consistently unmethylated group and plus 0.6 points in the consistently hypermethylated group. The epigenetic landscape, in other words, is largely frozen between the two surgeries.

The apparent transitions told a different and more instructive story. Tumors that flipped from hypermethylated to unmethylated had baseline methylation levels on average 13.5 percentage points lower than tumors that stayed hypermethylated, a difference that was highly statistically significant. Tumors that gained hypermethylation at recurrence had recurrence values on average 16.3 points lower than consistently hypermethylated tumors. In plain terms, the tumors that changed categories were clustered near the classification thresholds, where a small quantitative shift — whether from intratumoral heterogeneity, differences in sampling, assay variability, or modest epigenetic drift — is enough to move a tumor across the line. The authors conclude that most categorical status changes reflect variability at the margins of classification rather than true epigenetic reprogramming under therapeutic pressure, a distinction with real consequences for how clinicians should read a changed report.

The study also mapped methylation dynamics onto the temporal arc of the disease, using the interval between the two tissue collections as a surrogate for disease course. Among patients whose samples were collected at least three months apart, tumors that remained hypermethylated, lost hypermethylation, or gained hypermethylation all showed longer intervals between samples than tumors that stayed unmethylated. Consistently hypermethylated tumors had intervals 6.7 months longer than consistently unmethylated ones, and tumors that gained hypermethylation showed an 8.2-month difference, with both comparisons reaching statistical significance. The researchers interpret this descriptively: it mirrors the established association between MGMT hypermethylation and better response to alkylating chemotherapy, rather than implying that methylation changes themselves alter the disease trajectory. An exploratory geographic analysis added a curious footnote — frontal lobe tumors were more likely to remain hypermethylated at recurrence, at 41 percent, and less likely to remain unmethylated, at 45 percent, compared with tumors elsewhere in the brain.

To connect the molecular findings to actual clinical behavior, the team analyzed a separate retrospective cohort of 27 adult patients from two academic institutions, Rutgers Cancer Institute and Lenox Hill Hospital, with detailed treatment records. These patients were predominantly diagnosed with glioblastoma, which accounted for 74.1 percent of cases, and nearly all — 96.3 percent — received temozolomide after their initial surgery regardless of MGMT status, consistent with standard of care. At recurrence, 44.4 percent of the cohort was re-treated with the drug. The pattern of who got re-treated tracked the biomarker: temozolomide rechallenge was pursued in 54.5 percent of patients whose tumors remained hypermethylated, compared with 41.7 percent of those whose tumors stayed unmethylated, though the difference did not reach statistical significance in this small sample. Re-irradiation showed the inverse pattern, being more common among patients with consistently unmethylated tumors.

That treatment asymmetry echoes findings from larger clinical trials, including the DIRECTOR trial, which demonstrated that MGMT promoter methylation is a strong predictor of benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma. Retrospective analyses have likewise shown that patients with retained hypermethylation gain more from a second course of the drug, while those with unmethylated tumors are more often directed toward alternative systemic therapies, clinical trials, re-irradiation, or supportive care. What the new study adds is real-world evidence that clinicians are, in fact, weighing MGMT status at recurrence when making these calls — and a quantitative argument that the status they weigh is usually the same one measured months or years earlier at diagnosis.

The implications for laboratory practice may prove to be the study’s most durable contribution. Because binary classification remains the norm in clinical reporting, tumors with borderline methylation — those hovering near the 7 and 9 percent cutoffs — can be labeled in ways that obscure their true position on what is increasingly understood as a quantitative continuum. Prior work has shown that intermediate or low-level methylation is associated with less predictable response to temozolomide and diminished prognostic value compared with clearly unmethylated or robustly hypermethylated tumors. The new data suggest these borderline tumors form a biologically less stable subgroup, vulnerable to reclassification between surgeries for reasons that may have little to do with genuine epigenetic evolution. Routine quantitative reporting, the authors argue, would give oncologists the context needed to interpret a changed status appropriately — and to recognize when a change is more artifact than biology.

The authors are careful to acknowledge the limits of their analysis. Both cohorts were retrospective, introducing potential selection and sampling biases; the interval between surgeries is an imperfect proxy for progression-free survival; the commercial database lacked treatment details, precluding adjustment for therapy-related confounders; and the 27-patient clinical cohort was too small and underpowered for survival analyses, making its findings exploratory. The molecular data also cannot fully disentangle the contributions of intratumoral heterogeneity, sampling variability, and selective pressure from chemotherapy. Still, with one of the largest paired cohorts of recurrent glioma assembled to date and the integration of quantitative methylation percentages alongside categorical labels, the study makes a compelling case that MGMT assessment at diagnosis remains clinically reliable — and that reassessing it at recurrence, with numbers rather than just labels, could sharpen one of the most difficult decisions in brain tumor medicine.

Subject of Research: Stability of MGMT promoter methylation in recurrent glioma and its implications for temozolomide rechallenge

Article Title: Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

Article References: Noren, H., Pelofsky, G., Suffren, B., Mittelman, L., Yohn, C., Twyman, A., Febres-Aldana, C. A., Abramyan, A., Sertil, A., D’Amico, R. S., Sherman, J. H., & Vojnic, M. (2026). Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge. Journal of Neuro-Oncology, 179(3), Article 85. https://doi.org/10.1007/s11060-026-05778-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05778-y

Keywords: glioma, glioblastoma, MGMT promoter methylation, temozolomide, epigenetics, DNA methylation, biomarker, pyrosequencing, recurrent brain tumor, chemotherapy rechallenge, precision oncology, neuro-oncology

The logic behind the conventional approach is simple: because glioblastoma cells creep microscopically into surrounding tissue, the radiation field must be larger than the visible tumor. But histopathologic and preclinical studies have long shown that glioblastoma does not spread isotropically. Instead, it migrates preferentially along large white matter pathways, the bundled fiber tracts that connect distant brain regions. The tumor behaves less like an inflating balloon and more like water flowing through a network of pipes, racing along highways of myelinated axons while slowing at natural barriers. Yet this biological reality has never been systematically built into radiotherapy planning, until now.

A team led by Michael Wahl of the University of California, San Francisco, together with colleagues across UCSF’s radiation oncology, neurology, radiology and neurosurgery departments, has now translated that insight into a clinically workable technique. Their method uses diffusion-weighted MRI, which measures how freely water molecules diffuse through tissue. In organized white matter, water diffuses preferentially along the axis of the fiber bundles, a phenomenon called anisotropy. Tractography algorithms exploit this signal to reconstruct the trajectories of white matter fiber pathways throughout the entire brain, effectively drawing a wiring diagram of each individual patient.

The technical pipeline behind the study is a careful exercise in modern imaging science. Thirteen glioblastoma patients underwent 55-direction high angular resolution diffusion imaging on a 3 Tesla scanner as part of their postoperative radiation planning MRI, an acquisition of only seven to eight minutes. After correcting the data for head motion and eddy-current distortion using the FMRIB Software Library, the researchers fit both a tensor model and a higher-order Q-ball model with the open-source DIPY package, the latter to accurately resolve regions where fiber bundles cross. White matter, defined as voxels with fractional anisotropy above 0.15, was seeded densely, and a residual-bootstrap tractography approach estimated fiber orientations probabilistically, terminating streams when anisotropy fell below threshold or fibers bent more than sixty degrees.

Here is where the innovation crystallizes. The team selected all tractography streamlines passing within five millimeters of the visible tumor, the gross tumor volume delineated from the surgical cavity, contrast-enhancing regions and mass-like T2-FLAIR abnormality. From this subset they generated a scalar map in which every voxel stores its minimum white matter path length to the tumor, the shortest distance along actual fiber tracts rather than straight-line distance. The result is an anatomically informed expansion: the target flows along the superior cingulum bundle in one patient, crosses to the opposite hemisphere through the splenium of the corpus callosum in another, and in a third tracks along the inferior longitudinal fasciculus, precisely the routes along which those tumors later spread. In every one of the thirteen cases, the resulting contours respected natural anatomic boundaries that the standard circular expansion ignored.

The payoff appears in the numbers. When the researchers generated clinical target volumes by thresholding the path length maps at two centimeters and compared them, within the same patient, to the guideline-conformant two-centimeter isotropic expansion, the tractography-based volumes were a median of 67 cubic centimeters smaller, roughly a nineteen percent reduction, a difference that reached statistical significance. The one-centimeter variant shrank targets even more dramatically, by 39 percent on average, though at the cost of missing several recurrences captured by the standard volume. At three centimeters, the tractography volume converged with the standard one, as expected. These volumes were imported directly into the RayStation treatment planning system, demonstrating that the approach is compatible with routine clinical workflows rather than confined to research software.

The more consequential question is whether these sculpted volumes actually contain the places where tumors come back. To answer it, the team performed a patterns-of-failure analysis, rigidly registering each patient’s recurrence MRI to the planning scans and classifying recurrences as central, in-field, marginal or distant relative to each target definition. The median time to recurrence was twelve months. Ten of the thirteen recurrence volumes fell entirely within the conventional isotropic target, but twelve of thirteen were encompassed by the two-centimeter tractography-based volume, all while that volume was substantially smaller. In two cases, the recurrent tumor was clearly infiltrating along a major white matter tract inside the tractography target but outside the standard one, exactly the failure mode the technique was designed to prevent.

The clinical context makes these findings timely. Historical teaching held that ninety percent of glioblastoma recurrences occur within a two-centimeter margin of the original tumor, a figure that discouraged tinkering with target delineation. But more recent studies of patients treated with concurrent temozolomide, particularly those whose tumors carry methylation of the MGMT promoter and are therefore more drug-sensitive, have shown marginal or distant recurrence rates approaching forty percent, suggesting that current volumes may undertreat pockets of microscopic disease in some patients. At the same time, generous circular expansions irradiate substantial volumes of healthy brain, raising the specter of radiation necrosis and long-term neurocognitive decline. An approach that could simultaneously tighten targets and extend them along true routes of invasion promises the rarest of things in oncology: better coverage with less collateral damage.

The researchers are appropriately measured about what their study can and cannot claim. Thirteen patients cannot prove a statistical reduction in marginal or distant recurrences, and the pattern-of-failure analysis was observational and hypothesis-generating. Even demonstrating that a recurrence fell within a tractography target does not prove that treating that volume would have prevented it, since most patients still recur within the high-dose region regardless of technique. The small sample also prevented confident optimization of the tracking parameters and path length thresholds, and no dosimetric analysis of organ-at-risk sparing has yet been performed. Validation in a larger prospective cohort, with formal assessment of normal brain sparing through dose-volume statistics, is the clearly stated next step.

Still, as a proof of concept, the study is striking in its feasibility and simplicity. The imaging sequence adds only minutes to a standard planning MRI, the analysis relies on open-source tools, and the output drops directly into commercial treatment planning software. What the UCSF team has shown is that the brain’s own anatomy can be enlisted as a map of where an incurable tumor is likely to travel next, replacing a geometric convention inherited from decades-old CT studies with a personalized, biologically grounded contour. If larger trials confirm that two centimeters along a nerve fiber tract is worth more than two centimeters in a straight line, the humble circle that has defined glioblastoma radiotherapy for a generation may finally be retired, and one of medicine’s grimmest diagnoses may gain a small but meaningful edge.

Subject of Research: Tractography-based clinical target volume delineation for glioblastoma radiotherapy planning

Article Title: White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma

Article References: Wahl, M., Chapman, C. H., Morin, O., Jordan, K., Henry, R. G., Chang, S. M., Villanueva-Meyer, J. E., Mukherjee, P., Theodosopoulos, P., McDermott, M. W., Berger, M. S., Sneed, P., Braunstein, S. E., & Lupo, J. M. (2026). White matter pathlength maps from diffusion-weighted MRI tractography for radiotherapy target planning in glioblastoma. Journal of Neuro-Oncology, 179(3), Article 102. https://doi.org/10.1007/s11060-026-05789-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05789-9

Keywords: glioblastoma, diffusion-weighted MRI, tractography, radiotherapy planning, white matter, clinical target volume, patterns of failure, tumor recurrence, neuro-oncology, UCSF, temozolomide, medical imaging

In an effort to improve on those dismal numbers, veterinary oncologists have tested a series of combination chemotherapy protocols incorporating agents such as vincristine, cyclophosphamide, and dacarbazine alongside doxorubicin. None has proven clearly superior to single-agent doxorubicin, and most carry greater toxicity. One combination, however, generated genuine excitement: doxorubicin paired with dacarbazine, administered as a true concurrent combination for dogs with advanced-stage hemangiosarcoma, produced an objective response rate of 47.4 percent in a prospective study, although its impact on overall survival remains undefined. The catch is logistical and toxic. Dacarbazine must be given as an eight-hour intravenous infusion every three weeks, and beyond the usual myelosuppressive risks of neutropenia and thrombocytopenia, it is notorious for causing acute gastrointestinal upset that requires prophylactic antiemetic therapy.

That is where temozolomide enters the story. Temozolomide is an oral chemotherapeutic closely related to dacarbazine, but far easier to administer and generally well tolerated in dogs, with favorable safety data already available when it is combined with doxorubicin in canine lymphoma patients. In human medicine, temozolomide is the first-line chemotherapy for glioblastoma multiforme, a deadly brain cancer, and its mechanism of action is well characterized. Once in the bloodstream, the drug spontaneously hydrolyzes into its active metabolite, 5-(3-methyl-1-triazeno) imidazole-4-carboxamide, or MTIC. MTIC methylates nucleotide bases in DNA, with guanine as the most important target. The cell’s mismatch repair pathway then detects these methylated bases and attempts to repair them in a futile cycle that ultimately triggers apoptosis, the programmed death of the cancer cell.

That mechanism also explains why some tumors resist the drug. In cells with an intact mismatch repair system, sensitivity to temozolomide is governed largely by a DNA repair protein called O-6-methylguanine-DNA methyltransferase, or MGMT. MGMT works by directly removing the methyl groups that temozolomide installs, effectively erasing the damage before it can become lethal. When MGMT is overexpressed, the drug’s fingerprints are wiped away almost as fast as they are written, and the tumor survives. In human glioblastoma, this relationship is so reliable that testing MGMT status, particularly epigenetic silencing of the MGMT promoter, is routinely used to decide whether temozolomide is a viable option for a patient. The question for veterinary researchers was whether the same logic could be imported into canine hemangiosarcoma: if MGMT expression varied among tumors, it might serve as a biomarker to identify which dogs would benefit from adding temozolomide to doxorubicin.

A new study led by Brianna Moore, Julie Nguyen-Edquilang, and Matthew R. Berry at the University of Illinois set out to test exactly that hypothesis in the laboratory. The team worked with five canine hemangiosarcoma cell lines, named DHSA-1426, Emma Brain, Emma Spleen, FITZ, and SBHSA, along with a canine aortic endothelial cell line as a comparison. The cell lines had been shared by collaborators at the University of Minnesota, Colorado State University, and the University of Wisconsin-Madison. To anchor their measurements, the researchers used a human cervical cancer cell line, HeLa, and a pair of mouse glioma cell lines, one wild type and one engineered to carry a human MGMT knock-in, as controls. All cells were cultured under standard conditions at 37 degrees Celsius in a humidified incubator with five percent carbon dioxide.

The researchers measured MGMT at two levels. Quantitative PCR, using canine-specific TaqMan primers with GAPDH as the reference gene, quantified MGMT transcript abundance across three biological replicates with five technical replicates each. Western blotting, performed with a rabbit monoclonal antibody and normalized to the loading control beta-actin, assessed protein expression. The two approaches told a generally concordant story. Four of the five hemangiosarcoma cell lines, DHSA-1426, Emma Brain, Emma Spleen, and SBHSA, showed low or absent MGMT transcript and protein. FITZ was the striking exception, displaying the highest MGMT expression of the panel, roughly twenty-fold greater protein expression than the canine endothelial cell line based on normalized densitometry. The protein bands appeared at the expected sizes, approximately 37 kilodaltons in human controls and approximately 40 kilodaltons in canine cells, a slight species difference confirmed against UniProt database entries.

With the expression map in hand, the team turned to cytotoxicity testing using the sulforhodamine B assay. Cells were seeded in 96-well plates, pretreated for two hours with O6-benzylguanine, an inhibitor that depletes the functional pool of MGMT, and then exposed to temozolomide at concentrations ranging from 0.033 micromolar to 1000 micromolar for seven days. Because temozolomide is unstable in solution, it was dissolved fresh immediately before each experiment. Cytotoxicity values were normalized against a DMSO live-cell control and a raptinal control that induces complete cell death, allowing relative responses to be compared across conditions. The control cell lines behaved exactly as biology predicts. GL261 wild-type cells, which lack MGMT, were sensitive to temozolomide even without the inhibitor, while GL261 MGMT knock-in cells were strongly resistant, with IC50 values comparable to the hemangiosarcoma lines, until O6-benzylguanine pretreatment sensitized them, producing the largest drop in IC50 of any line tested.

The hemangiosarcoma results defied expectations. Every canine cell line proved resistant to temozolomide across the entire tested concentration range, regardless of MGMT status. FITZ, the only line expected to be sensitized by MGMT inhibition based on its high expression, remained stubbornly resistant, showing an undulating dose-response curve with no concentration-dependent effect in any of three biological replicates, and no reliable IC50 could be determined. DHSA-1426 likewise showed minimal cytotoxic response across the range, precluding curve fitting. In other words, MGMT expression status could not predict temozolomide sensitivity in canine hemangiosarcoma cells, and blocking MGMT did not rescue drug sensitivity even where the protein was abundant. The data point instead to an MGMT-independent resistance mechanism, and the authors hypothesize that mismatch repair deficiency is the culprit.

That hypothesis has independent support. A comprehensive analysis of microsatellite instability in canine cancers, a hallmark of mismatch repair defects marked by mutations accumulating in repetitive DNA sequences, found a surprisingly high incidence of 63 percent across canine tumors, with hemangiosarcoma among the tumor types showing elevated instability. If canine hemangiosarcoma is indeed frequently mismatch repair deficient, the implications extend well beyond temozolomide. Mismatch repair deficiency also means deficient methylated DNA goes unnoticed by the cell, undermining the drug’s lethal futile-repair cycle. More intriguingly, tumors with high microsatellite instability carry increased mutational burden and therefore heightened immunogenicity, making them particularly susceptible to immune checkpoint blockade. The authors suggest this provides biological rationale for moving beyond chemotherapy combinations entirely and exploring chemo-immunotherapy, pairing doxorubicin with agents such as PD-1 or PD-L1 inhibitors.

The study’s conclusions are a sober but valuable course correction. MGMT remains a highly promising predictive biomarker for temozolomide selection in human glioblastoma, but this in vitro investigation demonstrates that canine hemangiosarcoma cell lines resist the drug through a mechanism that MGMT testing cannot capture. On that basis, the authors conclude the data do not support clinical exploration of temozolomide, alone or combined with doxorubicin, for treating dogs with hemangiosarcoma. Instead, the findings redirect attention toward characterizing mismatch repair deficiency in canine hemangiosarcoma and toward immunotherapy-based strategies that exploit the high mutational burden such deficiency creates. For a disease that claims most of its canine victims within a year of diagnosis, a result that rules out one dead-end combination while pointing toward a biologically grounded alternative is a meaningful step forward for comparative oncology.

Subject of Research: MGMT expression and temozolomide resistance mechanisms in canine hemangiosarcoma cell lines

Article Title: Investigating MGMT expression as a resistance mechanism to temozolomide in canine hemangiosarcoma cell lines

Article References: Moore, B., Nguyen-Edquilang, J., & Berry, M. R. (2026). Investigating MGMT expression as a resistance mechanism to temozolomide in canine hemangiosarcoma cell lines. Veterinary Oncology, 3(1), Article 24. https://doi.org/10.1186/s44356-026-00076-1

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00076-1

Keywords: canine hemangiosarcoma, temozolomide, MGMT, doxorubicin, chemotherapy resistance, mismatch repair deficiency, microsatellite instability, veterinary oncology, DNA repair, immunotherapy, cell lines, dog cancer

The study focused on a molecularly defined subset of patients: those whose tumors carry methylation of the MGMT promoter, a chemical modification that silences a key DNA repair gene. This silencing matters enormously for treatment, because the chemotherapy drugs used against glioblastoma, temozolomide and lomustine, work by damaging tumor DNA. When the MGMT repair protein is suppressed, cancer cells cannot efficiently undo that damage, making them more vulnerable to the alkylating agents. Patients with MGMT-methylated tumors therefore respond better to chemotherapy, and the German CeTeG/NOA-09 trial demonstrated that these patients benefit from an intensified first-line regimen combining radiotherapy with both temozolomide and lomustine, also known as CCNU, rather than temozolomide alone.

Earlier work by a group led by Wiewrodt and colleagues had reported that among patients with MGMT-methylated, IDH-wildtype glioblastoma, those with blood group O lived longer than those with A, B, or AB blood types, an effect seen mainly in patients receiving standard temozolomide-based radiochemotherapy. But the association remained untested in patients receiving the intensified lomustine-temozolomide combination, and only a small fraction of the original cohort had received that regimen. The Bonn team, led by Julia Scheuble and Johannes Weller, set out to close that gap by examining an independent cohort treated uniformly under the CeTeG/NOA-09 protocol between 2008 and 2023.

The researchers assembled a cohort of 61 adults with newly diagnosed MGMT-methylated, IDH-wildtype glioblastoma, all of whom had documented ABO blood groups from routine preoperative typing and had received first-line radiochemotherapy with lomustine and temozolomide. Of these, 24 patients, or 39.3 percent, had blood group O, a proportion almost identical to the 39.2 percent prevalence of blood group O among German blood donors, which argues against any selection distortion. Baseline characteristics, including age, sex, Karnofsky Performance Status, and extent of surgical resection, were well balanced between the O and non-O groups, strengthening the credibility of the survival comparison.

The survival differences were substantial. Patients with blood group O lived a median of 42.1 months overall, compared with 23.7 months for patients with non-O blood groups, a difference that reached statistical significance with a log-rank p-value of 0.04. Progression-free survival, the time before the tumor began growing again, showed a similar trend: 21.8 months for blood group O versus 17.5 months for non-O groups, though this unadjusted comparison fell just short of significance. Median follow-up in the cohort was 56.1 months, and the majority of patients underwent surgery in the later years of the study period, reflecting the growing routine availability of molecular tumor characterization.

Crucially, the association survived statistical adjustment for the established prognostic factors. In multivariable Cox proportional hazards models accounting for age, extent of resection, and performance status, patients with non-O blood groups faced nearly double the hazard of progression, with a hazard ratio of 1.86, and more than double the hazard of death, with a hazard ratio of 2.29, compared with blood group O. Sensitivity analyses that sequentially removed individual covariates produced consistent estimates, with overall survival hazard ratios ranging from 2.02 to 2.42, indicating that the finding was not an artifact of any single adjustment variable. Tests of the proportional hazards assumption showed no violations, and salvage treatments at recurrence, including re-resection, re-irradiation, temozolomide rechallenge, bevacizumab, and regorafenib, were distributed similarly between the two blood group strata, suggesting that differences in second-line care did not drive the survival gap.

What could a blood type possibly have to do with brain cancer biology? The ABO system is defined by glycosyltransferase enzymes that decorate cell surfaces with specific sugar structures, and these glycans influence far more than transfusion compatibility. Experimental studies in non-glioma tumor models have linked fucosyltransferase activity, the enzymatic machinery that distinguishes blood group O from other types, to cellular mobility and resistance to apoptosis, the programmed cell death that chemotherapy is designed to trigger. In MGMT-methylated glioblastoma, where impaired DNA repair already heightens sensitivity to alkylating agents, the authors speculate that ABO-dependent glycosylation could theoretically modify how tumor cells respond to temozolomide or lomustine, altering the balance between treatment-induced damage and cellular survival.

The researchers are careful, however, to emphasize the limits of this mechanistic reasoning. There is currently no experimental evidence demonstrating a direct interaction between ABO glycosyltransferase activity, MGMT promoter methylation, and chemotherapy sensitivity in glioblastoma. The observed association could equally reflect differences in intrinsic tumor biology or the tumor microenvironment rather than a treatment-specific effect. The study itself carries the inherent constraints of a retrospective, single-center design with a limited sample of 61 patients, and the restriction to patients considered fit enough for intensified lomustine-temozolomide therapy produced a clinically selected population with relatively favorable performance status, limiting generalizability to frail patients. Residual confounding also cannot be excluded, and the 15-year study window may have introduced historical shifts in surgical technique, imaging, and salvage strategies, although the cohort was concentrated in the later years.

Despite these caveats, the consistency of the result across two independent cohorts, both restricted to MGMT-methylated patients and both showing the same direction of effect, gives the finding unusual weight for a biomarker study of this size. The Bonn cohort’s uniform treatment under a single protocol minimizes the treatment-related heterogeneity that has plagued earlier ABO studies, many of which predate the WHO 2021 integrated molecular classification of brain tumors and mixed together molecularly distinct entities. If validated in larger, multicenter cohorts, blood group typing, a test already performed routinely before any craniotomy, could become a virtually free addition to the prognostic toolkit, helping clinicians and patients calibrate expectations and potentially guiding the design of future trials.

The authors describe their results as hypothesis-generating, and the next step is translational: understanding whether ABO glycans genuinely modulate the response of glioma cells to alkylating chemotherapy, or whether blood group O simply tags some other, still unknown biological advantage. Either answer would deepen scientific understanding of how the most ancient of human genetic markers, the ABO system, interacts with modern cancer medicine. For now, patients with MGMT-methylated glioblastoma and blood group O can be told they carry a statistically favorable sign, while researchers pursue the biology that might one day turn that sign into a therapeutic target for everyone else.

Subject of Research: Association of ABO blood group O with survival outcomes in MGMT-methylated glioblastoma patients receiving lomustine-temozolomide radiochemotherapy

Article Title: Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine

Article References: Prognostic impact of blood group O in MGMT-methylated glioblastoma patients receiving radiochemotherapy with temozolomide and lomustine. (n.d.). https://doi.org/10.1007/s11060-026-05813-y

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05813-y

Keywords: glioblastoma, ABO blood group, MGMT promoter methylation, temozolomide, lomustine, radiochemotherapy, prognostic biomarker, overall survival, progression-free survival, CeTeG/NOA-09, glycosylation, neuro-oncology